Background-Receptor binding of complement C5a leads to proinflammatory activation of many cell types, but the role of receptor-mediated action during arterial remodeling after injury has not been studied. In the present study, we examined the contribution of the C5a receptor (C5aR) to neointima formation in apolipoprotein E-deficient mice employing a C5aR antagonist (C5aRA) and a C5aR-blocking monoclonal antibody. Methods and Results-Mice fed an atherogenic diet were subjected to wire-induced endothelial denudation of the carotid artery and treated with C5aRA and anti-C5aR-blocking monoclonal antibody or vehicle control. Compared with controls, neointima formation was significantly reduced in mice receiving C5aRA or anti-C5aR-blocking monoclonal antibody for 1 week but not for 3 weeks, attributable to an increased content of vascular smooth muscle cells, whereas a marked decrease in monocyte and neutrophil content was associated with reduced vascular cell adhesion molecule-1. As assessed by immunohistochemistry, reverse transcription polymerase chain reaction, and flow cytometry, C5aR was expressed in lesional and cultured vascular smooth muscle cells, upregulated by injury or tumor necrosis factor-␣, and reduced by C5aRA. Plasma levels and neointimal plasminogen activator inhibitor-1 peaked 1 week after injury and were downregulated in C5aRA-treated mice. In vitro, C5a induced plasminogen activator inhibitor-1 expression in endothelial cells and vascular smooth muscle cells in a C5aRAdependent manner, possibly accounting for higher vascular smooth muscle cell immigration. Conclusions-One-week treatment with C5aRA or anti-C5aR-blocking monoclonal antibody limited neointimal hyperplasia and inflammatory cell content and was associated with reduced vascular cell adhesion molecule-1 expression. However, treatment for 3 weeks failed to reduce but rather stabilized plaques, likely by reducing vascular plasminogen activator inhibitor-1 and increasing vascular smooth muscle cell migration. (Circulation. 2010;122:1026-1036 .) The online-only Data Supplement is available with this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.110.954370/DC1.
A therosclerosis is an inflammatory disease driven by the interaction of inflammatory cells and the vascular wall. 1 Complement components have been identified in neointimal plaques after vascular injury in mice 2 and in human atherosclerotic tissues, 3 and adverse cardiovascular events have been correlated with C5a plasma levels. 4 C5a is a potent soluble anaphylotoxic and chemotactic inflammatory mediator promoting the recruitment and activation of neutrophils and monocytes. 5 C5a specifically binds to its receptor C5aR (also named CD88), a rhodopsin-type receptor expressed in various cell types. In addition to immune cells (neutrophils, eosinophils, basophils, monocytes/macrophages, mast cells, dendritic cells, and T cells), C5aR has also been detected in nonimmune cells, including neuronal and endothelial cells (ECs), and in different tissues (lung, kidney, liver, spleen, intestine, skin, and heart). 6 Binding of C5a to C5aR leads to cellular activation, including adhesion and chemotaxis. 7 Enhanced surface and messenger RNA (mRNA) expression of C5aR was found in microvascular ECs after exposure to lipopolysaccharide, interferon-␥, and interleukin-6, concomitant with an upregulation of macrophage-inflammatory protein-2/ CXCL2 and macrophage chemoattractant protein-1/CCL2. 8 Stimulation of ECs with C5a increases the gene expression of adhesion molecules, 9, 10 cytokines, chemokines, and related receptors. 9, 11 
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In C5aR-deficient mice, IgG immune complex-induced inflammatory responses were attenuated in association with reduced neutrophil influx and microvascular permeability changes. 12 C5aR blockade improved survival in sepsis 13 and renal allografts 14 and reduced tubulointerstitial fibrosis, 15 implying an important role for C5aR in the mechanism of these inflammatory responses. The presence of C5aR has been found in human atherosclerotic plaque tissue by immunohistochemistry and mRNA analysis. 16 However, effects mediated by C5aR during arterial remodeling after injury have not been investigated, and no functional data on the C5a-C5aR complex in vascular smooth muscle cells (VSMCs) are available.
In the present study, the hypothesis that C5aR targeting may inhibit neointimal hyperplasia after arterial injury through the inhibition of receptor-mediated proinflammatory actions in vascular cells was tested. Short-term C5aR antagonist (C5aRA) and anti-C5aR monoclonal antibody (mAb) treatment for 1 week reduced plaque size, leukocyte recruitment, and vascular cell adhesion molecule (VCAM)-1 expression. In contrast, long-term treatment (3 weeks) reduced inflammatory cell recruitment and VCAM-1 expression; however, it also induced plasminogen activator inhibitor (PAI)-1-dependent migration of VSMCs to the neointima and stabilized plaques without reducing their size. The concomitant reduction of PAI-1 in ECs and smooth muscle cells (SMCs) after long-term C5aRA treatment in vivo in turn induced VSMC migration into the neointimal plaque. Moreover, we investigated the effects of C5a-C5aR blockade on PAI-1 and VCAM-1 regulation in VSMCs. Our results indicate a strong protective effect by short-term blockade of C5aR with C5aRA or anti-C5aR mAb on neointimal plaque formation, leukocyte recruitment, and adhesion molecule expression.
Methods

Mouse Model of Carotid Artery Injury
Six-to 8-week-old apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) mice (C57Bl/6 background) were fed an atherogenic diet containing 21% fat (0.15% cholesterol, 19.5% casein) for 1 week before and up to 3 weeks after arterial injury. Carotid artery injury was induced by 3 rotational passes of a 0.014-inch angioplasty guide wire. 17, 18 Alzet mini-osmotic pumps with C5aRA JPE-1375 (25 g/d per mouse; flow rate, 0.25 L/h) were placed 2 days before injury. One group of mice was treated for 1 week (nϭ10), and another group was treated for 3 weeks (nϭ12). Vehicle (saline)-treated mice served as controls (nϭ12 each). An additional third group was treated with C5aRA for only 1 week, but arteries were not removed before 3 weeks after wire injury (nϭ10 each). A confirmatory study was performed with anti-C5aR mAb (50 g per mouse every second day). Mice were treated intraperitoneally for either 1 week or 3 weeks (nϭ5 each). Controls (nϭ5 to 6) were treated with isotype antibody. Arteries were harvested by in situ perfusion fixation with 4% paraformaldehyde and embedded in paraffin. For mRNA isolation and VCAM-1 immunostaining, arteries were snap-frozen at Ϫ80°C. Animal experiments were approved by local authorities and complied with German animal protection laws.
C5aRA and C5aR-Blocking Antibody
The peptidomimetic C5aRA JPE-1375, provided by Jerini AG (Berlin, Germany), has been characterized. 19 The potent inhibition of human C5aR and high activity on murine C5aR makes JPE-1375 suitable for testing in mouse models. 19 The specific binding and activity of the C5aR-blocking mAb (clone 20/70, rat anti-mouse IgG2b, generated by J. Zwirner, Gö ttingen, Germany) were characterized previously by in vitro and in vivo studies. 20 -22 The functional grade isotype control antibody was purchased from eBioscience.
Morphometry, Immunofluorescence, and Enzyme Histochemistry
For the quantification of neointimal and medial areas, 6 sections from the paraformaldehyde-fixed and paraffin-embedded carotid artery from each mouse (identical section numbers 2, 12, 22, 32, 42, and 52), each 5 m in thickness, 50 m apart, and within 250 and 500 m from the bifurcation, were taken. These sections were subjected to Movat's pentachrome staining and analyzed by computerized planimetry (Diskus software, Hilgers, Kö nigswinter, Germany) to measure the neointimal area between the internal elastic lamina and the lumen and the medial area demarcated by the external and internal elastic lamina with negligible error and variability. Thus, these values represent individual measurements and not repeated measures. Given that the sections cover an identical segment of the vessel and are separated by an identical and defined distance, the mean of these 6 measurements represents an approximation of the neointimal and medial volume within that segment in a given mouse. Similarly, neointimal cell content was determined in paraformaldehyde-fixed and paraffinembedded serial sections.
Without systematic errors in deriving these means and with consideration that the biological variability is due to the longitudinal changes in neointimal plaque morphology, the means from nϭ10 to 12 mice were appropriately analyzed by Student t test, which implicitly accounts for assessing variability in a biological model. After the normality test was performed, the data from Figure 1E and 1G (nϭ5) were analyzed by a nonparametric Mann-Whitney test.
For immunohistochemistry, antibodies against Mac-2 (CL8942AP; Cedarlane, Burlington, Ontario, Canada), Ly6G (clone 1A8; BD PharMingen, San Diego, Calif), and C5aR (CD88, clone 10/92; Serotec, Oxford, UK) were used and visualized by the immunohistochemical avidin-biotin complex method with alkaline phosphatase enzyme development (Vector Laboratories, Ontario, Canada). Cells were counterstained by Mayer hemalaun and were quantified by counting positively stained cells relative to total cell number in the neointima. ␣-Smooth muscle actin (SMA) (clone 1A4; Dako, Glostrup, Denmark), PAI-1 (GenWay Biotech Inc, San Diego, Calif), and VCAM-1 on acetone-fixed cryosections (CD106, clone 429; BD PharMingen) were visualized by fluorescein isothiocyanate (FITC)-conjugated secondary antibody (Jackson ImmunoResearch, West Grove, Pa) and quantified by determining positively stained cell area relative to neointimal and medial area. Neutrophils were detected by specific esterase staining with naphthol-AS-Dchloracetate (Sigma, Munich, Germany). Double immunofluorescence staining of C5aR and PAI-1 with ␣-SMA was detected by secondary donkey anti-rabbit Cy-3 and donkey anti-mouse-FITC antibodies (Jackson ImmunoResearch). Appropriate IgG antibodies served as isotype controls. Right carotid arteries served as tissue controls. All images were recorded with the use of a Leica DMLB fluorescence microscope (Wetzlar, Germany).
Cells
Mouse aortic SMCs and ECs were isolated as described in the online-only Data Supplement. Human umbilical vein ECs and human coronary artery SMCs were purchased (PromoCell, Heidelberg, Germany).
Measurement of Serum Lipid Levels
Serum triglyceride, total cholesterol, and high-density and lowdensity lipoprotein cholesterol fractions were measured by standard laboratory enzymatic colorimetric assays.
PAI-1 Enzyme-Linked Immunosorbent Assay
Functional PAI-1 concentration in citrate plasma was analyzed by a mouse PAI-1 total antigen enzyme-linked immunosorbent assay (ELISA) kit (Loxo GmbH, Heidelberg, Germany). Total PAI-1 antigen in human cells was detected in supernatants by a human PAI-1 ELISA kit (American Diagnostica GmbH, Darmstadt, Germany). Cells were stimulated with recombinant human C5a (500 ng/mL; Sigma), tumor necrosis factor (TNF)-␣ (10 ng/mL), or recombinant mouse C5a (100 ng/mL; BD PharMingen) and pretreated with C5aRA (2.5 g/mL) for 16 hours at 37°C and compared with unstimulated (control) cells.
Reverse Transcription and Polymerase Chain Reaction
For RNA analysis, total RNA was isolated from the targeted area on a microscopic slide with the use of the Pinpoint slide RNA isolation system (Zymo Research, R-1003, Orange, Calif) and reverse-transcribed into cDNA with the use of Moloney Murine Leukemia Virus Reverse Transcriptase (Invitrogen, Carlsbad, Calif). Reverse transcription polymerase chain reaction (RT-PCR) was performed with the use of TaqMan Gene Expression Master Mix and real-time specific primer pairs (Applied Biosystems, Foster City, Calif). The expression levels of the target genes were quantified by real-time PCR by the ratio of complement C5aR (CD88) (Mm01268318_s1) and VCAM-1 (CD106) (Mm01320970_m1) to 18sRNA (Hs99999901_s1) levels. C5aR and VCAM-1 levels were normalized according to the respective GAPDH mRNA levels. For each group, the normalized value in the tissue that showed the lowest expression was used as a calibrator (set to 1), and remaining samples were displayed as fold changes (see the online-only Data Supplement).
Flow Cytometry
Cells were stained with C5aR (anti-mouse CD88-phycoerythrin rat IgG2a; Serotec), anti-human CD88-FITC mouse IgG2a (Genway Biotech Inc), and anti-mouse CD106 (VCAM-1)phycoerythrin rat IgG2a (Abcam, San Francisco, Calif) antibodies as isotype controls, respectively, for 30 minutes on ice. Cells were analyzed in a FACSCalibur flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ). At least 10 000 gated cells were acquired and analyzed with the use of CellQuestPro software. Experiments shown are representative of results from 3 independent cultures from each group of mice. 
Results
Effect of C5aRA and Anti-C5aR mAb on Neointimal Formation
To investigate the effect of C5aRA and anti-C5aR mAb treatment on accelerated plaque formation, we used a model of wire-induced neointimal hyperplasia in Apoe Ϫ/Ϫ mice fed an atherogenic diet. Mice were treated with C5aRA by mini-osmotic pumps or with anti-C5aR mAb intraperitoneally for 2 different time periods (1 week and 3 weeks) after injury. Treatment with C5aRA and anti-C5aR mAb was well tolerated, and no adverse effects, infections, thrombosis, or bleeding disorders were observed. After 1 week of treatment with C5aRA, neointimal area was significantly reduced compared with vehicle-treated controls, whereas medial area was unchanged ( Figure 1A and 1B). However, after 3 weeks of treatment, the neointimal plaque size was not altered, whereas the medial area was significantly increased ( Figure 1C and 1D) . Similarly, plaque size was significantly reduced after anti-C5aR mAb treatment for 1 week without changes in medial area ( Figure 1E and 1F). After 3 weeks of treatment, however, neointimal and medial areas were unaltered ( Figure 1G and 1H). Because changes in the lipid profile have been observed in complement-deficient mice, we analyzed lipid levels. Compared with controls, C5aRA-treated mice did not display significant differences in serum triglyceride, total cholesterol, or low-density or high-density lipoprotein cholesterol levels ( Table I in 
Effects of C5aRA and anti-C5aR mAb on Cellular Composition of Neointimal Lesions
We next investigated the cell content in carotid artery sections by immunohistochemistry. The relative content of VSMCs quantified by positive staining for ␣-SMA was not significantly different after 1 week of treatment between C5aRA-treated and control mice in either the neointima or media (Figure 2A and 2B) . Notably, treatment for 3 weeks resulted in a significant increase of ␣-SMA ϩ area in the neointima of C5aRA-treated mice compared with controls, whereas medial SMCs were slightly reduced ( Figure 2C and 2D). In contrast, the relative content of Mac-2 ϩ macrophages ( Figure 2E ) and neutrophils ( Figure 2F ) was significantly decreased in the neointima of C5aRA-treated mice versus controls after both 1 and 3 weeks. Similarly, treatment with anti-C5aR mAb reduced the neointimal SMC content, as assessed by ␣-SMA ϩ area, after 3 weeks, as well as the neointimal content of C5aR ϩ , Mac-2 ϩ cells, and neutrophils at both time points of treatment ( Figure IA 
C5aR Expression in Mouse Neointimal Plaque Tissue and in VSMCs In Vitro
Expression of C5aR mRNA has been detected in human atherosclerotic plaque. 16 ECs and macrophages 23 in atherosclerotic lesions were found to express C5aR, and the effect of C5a has been investigated. 6 After vascular injury, VSMCs show increased proliferation, migration, and synthetic capacity and play a critical role in vascular remodeling. 24 In response to TNF-␣ and interferon-␥, VSMCs produce complement components, 24 but the function of C5aR on VSMCs has not been investigated. In the present study, we analyzed C5aR expression in mouse carotid arteries after wire injury in vivo and in VSMCs in vitro. Compared with controls, C5aRA significantly reduced the number of C5aR ϩ cells after 1 and 3 weeks of treatment ( Figure 3A) . Compared with uninjured carotid arteries, C5aR mRNA was increased 3.5-fold in carotid arteries 1 week after injury and remained elevated at 3 weeks, and treatment with C5aRA reduced the upregulation of C5aR mRNA at both time points but had no effect in uninjured carotid arteries ( Figure 3B ). Using double immunostaining for colocalization, we identified C5aRexpressing cells in the neointima as ␣-SMA ϩ VSMCs ( Figure 3C) , ECs, and monocytes/macrophages (data not shown). Thus, activation of the C5a-C5aR axis after arterial injury likely reflects an influx of C5aR ϩ monocytes or neutrophils and augmented transcription in resident tissue macrophages, VSMCs, and ECs.
We further studied C5a-C5aR-mediated actions in VSMCs in vitro. Flow cytometry and RT-PCR revealed that human and mouse VSMCs express C5aR. The slight surface expression of C5aR was detected in unstimulated control human coronary artery SMCs and by stimulation with C5a (data not shown) and was markedly upregulated by TNF-␣ ( Figure  3D ). Similar expression was detected in mouse aortic SMCs ( Figure 3F ). Expression of C5aR mRNA was determined by RT-PCR analysis in unstimulated (control) and TNF-␣stimulated cells. Unstimulated cells express C5aR transcripts, and a 2-to 2.5-fold increase in mRNA levels was seen in TNF-␣-stimulated human coronary artery SMCs and mouse aortic SMCs ( Figure 3E and 3G ).
C5aRA Treatment Reduces VCAM-1 and PAI-1 Expression in Carotid Arteries
Stimulation of ECs with C5a has been shown to increase gene expression for cell adhesion molecules such as VCAM-1. 9 In atherosclerotic lesions, VCAM-1 was selectively upregulated in VSMCs, 25 and blocking VCAM-1 interactions reduced firm monocyte adhesion to arteries of Apoe Ϫ/Ϫ mice under shear stress. 26 The expression of VCAM-1 was quantified by immunostaining for CD106 in carotid arteries. The lower inflammatory cell content was associated with a significant reduction of VCAM-1 staining in both neointimal and medial areas after C5aRA and anti-C5aR mAb treatment for 1 and 3 weeks ( Figure 4A through 4D and Figure IE in the online- only Data Supplement). The uninjured right carotid arteries did not express VCAM-1 (data not shown). The expression of VCAM-1 mRNA was increased Ͼ3-fold in control mice after 1 week of wire injury but only 1.3-fold after 3 weeks compared with uninjured carotid arteries ( Figure 4E ). This supports the importance of early adhesion molecule expression in the pathogenesis of vascular injury. Treatment with C5aRA persistently reduced VCAM-1 mRNA to below the levels of uninjured controls at both time points ( Figure 4E ) but had no effect on VCAM-1 mRNA levels in uninjured arteries. These data indicate that the beneficial effects of C5aR targeting attenuating inflammatory cell recruitment are mediated by reducing VCAM-1.
To explore the mechanism for elevated neointimal SMC content after long-term C5aR targeting, we investigated PAI-1. Migration of VSMCs plays an important role in neointimal formation after vascular injury, 27 and PAI-1 may modulate vascular remodeling by regulating vascular cell migration through its capacity to inhibit urokinase plasminogen activator and/or to block interactions of cells and vitronectin in the extracellular matrix. 28 Whereas C5a can induce PAI-1 in macrophages, 23 it has not been tested whether C5a induces PAI-1 in ECs and VSMCs. As assessed by ELISA, plasma levels of PAI-1 were increased almost 4-fold 1 week after wire injury and remained elevated at 3 weeks compared with uninjured mice and were significantly reduced by C5aRA treatment at both time points but not at baseline ( Figure 4F ). Neointimal PAI-1 was examined by quantitative immunohistochemistry. Uninjured right carotid arteries did not express PAI-1 (data not shown). After wire injury, PAI-1 was expressed in neointimal lesions and was significantly reduced in C5aRA-treated mice at both time points ( Figure 4G ). Expression of PAI-1 was seen in colocalization with neointimal lesions and a few medial SMCs in carotid arteries of control Apoe Ϫ/Ϫ mice and in acellular areas ( Figure 4H ). Staining was also detected in ECs and macro- phages (data not shown). Thus, C5aR regulates neointimal PAI-1 expression after arterial injury, which can be inhibited by C5aRA. This inhibition may entail increased VSMC migration into the neointima, which may stabilize plaques but may also limit the beneficial effects of C5aRA on neointimal hyperplasia at 3 weeks.
Regulation of VCAM-1 and PAI-1 by C5a-C5aRA Interaction In Vitro
To confirm the in vivo findings on VCAM-1 regulation, additional in vitro experiments were performed in primary cultures of mouse aortic SMCs. In agreement with our in vivo data that uninjured carotid arteries did not express VCAM-1, flow cytometry analysis revealed that unstimulated mouse aortic SMCs did not express VCAM-1 ( Figure  5A ). C5a-induced VCAM-1 expression in mouse aortic SMCs was blocked by C5aRA treatment (Figure 5A ).
Previous studies have shown that PAI-1 deficiency in SMCs enhances flow-induced SMC migration, which was attenuated but not completely inhibited in the presence of ECs, 29 whereas shear flow increased wild-type SMC migration in the presence of PAI-1 Ϫ/Ϫ ECs. 30 Thus, concomitant reduction of PAI-1 in lesional SMCs and ECs by C5aRA treatment may entail migration of VSMCs into neointimal plaques after 3 weeks. Additional in vitro analysis in cell supernatants with sensitive ELISA demonstrated that C5a induces PAI-1 secretion in mouse aortic SMCs, aortic ECs ( Figure 5B ), human coronary artery SMCs, and human umbilical vein ECs ( Figure 5C ) compared with control cells. This induction of PAI-1 was blocked by C5aRA only in stimulated cells ( Figure 5B and 5C ). Together, our data indicate that short-term treatment with C5aRA for 1 week was effective for reducing plaque size and inflammatory cell recruitment by regulating adhesion molecule expression in vascular cells. Long-term treatment for 3 weeks mediated converse effects due to induction of PAI-1-dependent migration of VSMCs into the neointimal plaque.
Effectiveness of Short-Term Treatment With C5aRA After 3 Weeks of Wire Injury
We performed additional experiments to confirm the effectiveness of short-term treatment for 1 week. We hypothesized that the effect of short-term treatment would persist when neointimal VSMC accumulation is prevented because of long-term downregulation of PAI-1. Therefore, mice were treated for only 1 week after wire injury and then euthanized after 3 weeks. Neointimal plaque size was significantly reduced in C5aRA-treated compared with control mice, whereas medial area was not altered ( Figure 6A and 6B) . No difference in SMC content was seen in either neointima or media ( Figure 6C ). In contrast, the contents of Mac-2 ϩ monocytes/macrophages ( Figure 6D ), C5aR-expressing cells ( Figure 6E ), and neutrophils ( Figure 6F ) were significantly reduced in C5aRA-treated compared with control mice. Thus, treatment with C5aRA for 1 week effectively protects against neointima formation after wire injury.
Discussion
Our data show for the first time that inhibition of complement C5aR, with the use of a peptidomimetic C5aRA or a blocking anti-C5aR mAb, limits neointimal formation after wire injury in atherosclerosis-prone Apoe Ϫ/Ϫ mice. Short-term treatment with C5aRA and anti-C5aR mAb for 1 week was sufficient to reduce neointimal plaque area, inflammatory cell recruitment, and VCAM-1 expression in carotid arteries. However, 3-week treatment with C5aRA and anti-C5aR mAb failed to further reduce plaque size, which was due to increased SMC migration into the neointima. Additional in vitro and in vivo experiments indicate functional activity of the C5a-C5aR complex on human and mouse VSMCs through PAI-1 and VCAM-1 expression. An additional study confirmed the protective effects of short-term C5aRA treatment that persisted for 3 weeks after injury.
Investigation of the cellular content in carotid artery sections revealed a strong reduction in C5aR-bearing cells after C5aRA treatment, which was consistent with reduced mRNA expression. Further characterization by immunohistochemistry indicated that these cells predominantly (or primarily) occur in neointimal plaque area and colocalize with luminal SMCs, ECs, and macrophages. SMCs in uninjured right carotid arteries did not express C5aR. This is in agreement with a study showing that C5aR is present in inflammatory cell-rich regions of human atherosclerotic plaques, whereas normal human arterial tissue was negative for C5aR. 31 The reduction in C5aR-expressing cells after 3 weeks of treatment was lower than after 1 week of treatment, which can be explained by the increased content of C5aRexpressing neointimal SMCs. Thus, these data indicate an activation of the C5a-C5aR axis in the arterial wall after injury, reflecting an influx of C5aR-expressing monocytes and an augmented transcription of C5aR in resident tissue macrophages, VSMCs, and ECs.
The recruitment of inflammatory cells into neointimal sites requires a series of coordinated signals, including the upregulation of adhesion molecules. The C5aR-mediated upregulation of adhesion molecules has been investigated previously in ECs and macrophages in some respects 10, 23 ; however, experiments on VSMCs are still lacking. Neointimal SMCs display a proadhesive phenotype on constitutive upregulation of different chemokines. 27 Our previous study has shown that luminal SMCs express junctional adhesion molecule-C and thereby contribute to initial monocyte recruitment into neointima. 32 Expression of VCAM-1 in medial SMCs precedes or coincides with mononuclear cell infiltration, suggesting a role of VCAM-1 in early atherogenesis. 25 VCAM-1 expression was implicated previously as a marker of transition of VSMCs to the synthetic phenotype within atherosclerotic lesions. 33 Its expression was selectively upregulated on SMCs in the neointima of atherosclerotic lesions, but no expression was found on medial SMCs in adjacent areas of the vessel devoid of lesion. 25 In this study, we found a strong upregulation of VCAM-1 at protein and mRNA levels in control mice 1 week after injury, which could be impaired by C5aRA treatment. The expression of VCAM-1 on the intimal and medial SMCs could thus play an important role in the retention of monocytes/macrophages within the lesion. In vitro experiments with primary mouse aortic SMCs demonstrated that C5a-induced VCAM-1 upregulation can be blocked with C5aRA. These data confirm our in vivo finding that C5a-C5aR interactions are involved in the upregulation of VCAM-1 after wire injury.
Migration of VSMCs from the media is a key event in progressive intimal thickening, leading to atherosclerosis and restenosis. On the other hand, increased numbers of VSMCs in the atherosclerotic plaque reflect a more stable plaque phenotype. 24 We observed in our study that long-term C5aRA and anti-C5aR mAb treatment elevated the accumulation of VSMCs within the neointima. PAI-1 is a major inhibitor of the fibrinolytic system, and elevated plasma levels of PAI-1 have been associated with occlusive vascular diseases and atherothrombosis. 34, 35 We report here the first evidence about the C5a-C5aR-mediated regulation of PAI-1 in vascular cells and its role in neointima formation. Early after vascular injury, the PAI-1 concentration was elevated in plasma, and the VSMCs in the neointima of carotid arteries showed increased PAI-1 expression, which could be reduced by C5aRA treatment. PAI-1 deficiency in SMCs has been shown to enhance flow-induced SMC migration. 29 In agreement with these findings, VSMCs explanted from SM22-PAI-knockin mice exhibited a 2-fold greater expression of PAI-1 and an attenuated migration pattern. 36 Moreover, flow-induced SMC migration was attenuated when PAI-1 Ϫ/Ϫ SMCs were cultured in the presence of ECs. 29 Thus, PAI-1 expression in VSMCs plays a role in limiting flow-induced VSMC migration. On the other hand, wild-type SMC migration was increased in the presence of PAI-1 Ϫ/Ϫ ECs, an effect that was reversed by addition of exogenous PAI-1. 30 These data clearly indicate that concomitant PAI-1 deficiency in both ECs and VSMCs leads to an amplified effect on VSMC migration. Our in vitro data indicate that C5a-mediated upregulation of PAI-1 in both ECs and VSMCs can be blocked after pretreatment of the cells with C5aRA, which may be one of the predominant mechanisms responsible for controlling VSMC migration and the process of vascular remodeling.
Our in vitro study investigates for the first time the effect of the C5a-C5aR-mediated action on the function of VSMCs. In the present study, we report that human and mouse VSMCs express C5aR at mRNA and protein levels, which were markedly increased after TNF-␣ stimulation. In the context of arterial neointima formation, we identify a specific role of the C5aR in the regulation of VCAM-1 and PAI-1 in VSMCs. Of note, C5aRA treatment did not affect cell viability in vitro. However, C5a blockade reduces thymocyte apoptosis in sepsis through the inhibition of caspase activation, 37 and C5aRA reduces ischemia-induced apoptosis in the kidney. 14 Thus, the exact molecular mechanisms regulating apoptosis by the C5a-C5aRA interaction remain to be elucidated.
The results of studies obtained with the use of an antagonist or knockout mice in atherosclerosis are often divergent and sometimes even contradictory. In complement-deficient animals, only 1 study in rabbits has found a protective effect of C6 deficiency. In contrast, atherosclerotic lesion formation was either unchanged or increased in C5-, C3-, and C1qdeficient-mice. 38, 39 C3 was shown to be necessary for stabilizing the plaque phenotype, whereas C1q provided a protective function, possibly by accelerating the clearance of apoptotic cells. In contrast, transient complement blockade with the complement receptor-related gene y-Ig (Crry), a recombinant protein of the mouse membrane complement inhibitor, or C1-esterase inhibitor provided protection against vein-graft thickening 40 and neointima formation in mice. 2 In a recent study, C5aR deficiency had protective effects in an acute model of inflammatory bowel disease but was disadvantageous in chronic inflammation. These data strongly support that C5aRA may be beneficial primarily for disease states in which complement is acutely activated. 41 Recent evidence suggests that anaphylatoxins regulate cell apoptosis, lipid metabolism, and innate and adaptive immune responses through their impact on T cells and antigen-presenting cells, as well as by modulating B-cell function. C5a has been reported to play a role in the trafficking and migration of various B-cell populations. 42 Anaphylatoxins can further influence specific T-cell responses. C3 deficiency, C3 depletion, and C5a deficiency have been associated with reduced T-cell responses. 43, 44 Antigen presentation by dendritic cells is augmented by TLR2 and C5aR signaling, resulting in a vigorous Th1 response. 45 In contrast, antigenpresenting cells lacking C5aR signaling generate mainly Th17 cells and induce Foxp3 ϩ Treg through enhanced transforming growth factor-␤ secretion. 45 The C5a-C5aR interaction directly modulates the dendritic cell activation state, subsequently upregulating dendritic cell function in allostimulation. 46 Not only are C3aR and C5aR expressed on dendritic cells and naive, unstimulated CD4 ϩ T cells, but both receptors are upregulated on antigen challenge. 47 In addition, C5a generation and its receptor upregulation have been linked to costimulation by B7-CD28 and CD40-CD40L molecules. 46, 47 A recent study further revealed that decayaccelerating factor (or CD55), an intrinsic complement regulator controlling C3a/C5a generation and subsequent C3aR/ C5aR activation, modulates the response to vascular injury. 48 Thus, on the basis of its strong proinflammatory properties, targeting C5aR has been considered an attractive pharmacological target in acute inflammation. However, long-term approaches should account for direct or indirect effects of anaphylatoxin receptor signaling on adaptive immune responses, cell apoptosis, migration, and tissue regeneration/ fibrosis that may affect such treatment.
In summary, we demonstrated in the present study a crucial role of C5a-C5aR action in the acceleration of neointima formation after vascular injury and showed that C5aR blockade provides a rationale for the potential use of C5aRA and C5aR-blocking antibody in clinical practice under conditions in which the acute onset of vascular cell and complement system activation promotes pathogenesis and disease progression (eg, for the prevention of restenosis after vascular intervention).
